WOBURN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (“PDT”), today announced that on February 23, 2026, the U.S. Patent Trial and Appeal Board (the “Board”) issued a Final Written Decision finding all challenged claims of Sun Pharmaceutical Industries, Inc.’s U.S. Patent No. 11,697,028 (the “’028 Patent”) to be unpatentable. As previously disclosed in Biofrontera’s filings ...

LONDON, February 26, 2026 – Stolt-Nielsen Limited (Oslo Børs: SNI) announced today that the Company's Board of Directors recommended a final dividend for 2025 of $1.00 per Common Share, payable on May 6, 2026 to shareholders of record as of April 22, 2026. The shares will trade ex-dividend on and after April 21, 2026. The dividend, which is subject to shareholder approval, will be voted on at the Company's Annual General Meeting of Shareholders scheduled for April 16, 2026 in Bermuda. If approved, this will ...

Recognized expert in cancer biology, RNA biology and translational therapeutics with 20 years of experience in preclinical oncology drug discovery and developmentTAMPA, Fla. and LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced the appointment of Prafulla Gokhale, Ph.D., Director of the Experimental Therapeutics Core and the Lurie Family Imaging Ce ...

Geneva, Switzerland, Feb. 26, 2026 (GLOBE NEWSWIRE) -- SEALSQ Corp (NASDAQ: LAES) ("SEALSQ" or "Company"), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced that it will present its Quantum Security technology and strategic roadmap at the Cantor Global Technology & Industrial Growth Conference, taking place from March 10–11, 2026, at the New York Hilton Hotel in NYC. SEALSQ’s CEO, Carlos Moreira, will participat ...

By combining Thomas’s sourcing technology and marketing tools with Maryland MEP’s reach, the partnership aims to fortify the Maryland supply chain and position local manufacturers for growthNORTH BETHESDA, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Thomas, a leading digital platform connecting industrial buyers with more than 500,000 suppliers, announced a strategic partnership with Maryland Manufacturing Extension Partnership (Maryland MEP) to accelerate the growth and digital maturity of manufacturers across ...

Core Insights - TIAN RUIXIANG Holdings Ltd. has significantly increased its Bitcoin investment from 15,000 to 30,000 BTC, reflecting strong confidence in its strategic vision and positioning in the AI-crypto landscape [1][2]. Group 1: Strategic Partnership and Investment - The strategic investor has committed an additional 15,000 BTC, bringing the total investment to 30,000 BTC, valued at over $2.0 billion at current market prices [2]. - This investment enhances TIRX's balance sheet with a highly liquid digital asset, reinforcing the investor's belief in TIRX's potential to innovate in AI-driven finance [2][5]. Group 2: Innovation and Product Development - The expanded partnership will accelerate the development of next-generation solutions, including AI-powered crypto trading and risk management systems [3][4]. - TIRX aims to create scalable and secure decentralized application ecosystems and innovative AI-crypto fusion products tailored for both institutional and retail investors [4]. Group 3: Market Position and Future Outlook - With the revised agreement, TIRX solidifies its position as a leader in the AI-crypto convergence, gaining financial resilience and strategic flexibility for aggressive expansion [5]. - The company views market corrections as opportunities for growth, positioning itself to lead the AI-crypto revolution for the long term [6].

-- FemBloc becomes the latest Femasys product to achieve MDSAP certification, building on a proven track record of compliance -- ATLANTA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today that its FemBloc permanent birth control system has achieved certification under the Medical Device Single Audit Program (MDSAP). The MDSAP certificati ...

Core Insights - Broadcom has begun shipping the industry's first 2nm custom compute SoC utilizing its 3.5D eXtreme Dimension System in Package (XDSiP) platform, which integrates advanced semiconductor technologies for enhanced performance and efficiency [1][3] Group 1: Technology and Innovation - The 3.5D XDSiP platform is foundational for next-generation XPUs, enabling high signal density, power efficiency, and low latency to meet the demands of large-scale AI clusters [2] - The integration of 2.5D techniques and Face-to-Face (F2F) technology in the 3.5D XDSiP allows for independent scaling of compute, memory, and network I/O in a compact form factor [2][3] - The launch of this technology represents a significant milestone in semiconductor integration, combining 2nm process innovation with advanced 3D integration to enhance compute density and energy efficiency [3] Group 2: Strategic Partnerships and Market Impact - Broadcom's collaboration with Fujitsu highlights the strategic importance of the 3.5D XDSiP technology in supporting Fujitsu's FUJITSU-MONAKA initiative for high-performance, low-power processors [3] - The advancements in Broadcom's 3.5D platform capabilities are set to support a broader customer base, with shipments expected to commence in the second half of 2026 [3]

Operates Two Facilities with an Additional Two in Development in Costa Rica Port Jefferson, NY, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Digerati Technologies, Inc., (“Digerati,” the “Company,” “we,” “our” or “us”) (OTCID: DTGI), a data center, power solutions and telecom services provider, is pleased to announce it has acquired a 25% equity stake of In-Pursuit Investments (“In-Pursuit”), a developer and operator of Green Data Centers, Energy projects, and advanced digital infrastructure in Costa Rica and Latin Am ...

Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day hospital discharge Four systemic sclerosis patients and the first idiopathic inflammatory myopathy patient treated with FT819; First systemic sclerosis patient reaching 3-month evaluation timepoint shows meaningful disease improvement using less-intensive conditioning chemotherapy FT819 Phase 1 enrollment expanded across 16 clinical sites in the U.S., U.K. ...